MBBS, FCPS (Radiotherapy)
Cancer Specialist & Radiation Oncologist
Assistant Professor, Radiotherapy
National Institute of Cancer Research & Hospital
Dr. Shahida Alam Lima’s Chamber & Appointment
Comfort Diagnostic Center, Dhanmondi
Address: 167/B, Green Road, Dhanmondi, Dhaka – 1205
Visiting Hour: 5pm to 7pm (Sun, Tue & Thu)
Appointment: +8801731956033
Labaid Cancer Hospital & Super Speciality Center
Address: 26, Green Road, Dhaka
Visiting Hour: 5pm to 7pm (Sat, Mon & Wed)
Appointment: +8809666710001
Dr. Shahida Alam Lima: Expert in Clinical & Radiation Oncology
Dr. Shahida Alam Lima is a distinguished Oncologist practicing in Dhaka, known for her expertise in treating various forms of cancer through advanced radiotherapy and clinical management. She balances a significant academic role with active clinical practice, ensuring her patients receive evidence-based and compassionate care.
Academic and Professional Profile
Dr. Lima holds high-level certifications that underscore her specialized skills in cancer treatment:
- MBBS: Bachelor of Medicine and Bachelor of Surgery.
- FCPS (Radiotherapy): Fellow of the Bangladesh College of Physicians and Surgeons. This prestigious fellowship signifies her mastery of radiation oncology and the comprehensive management of malignant diseases.
In her academic and public service capacity, she serves as an Assistant Professor in the Department of Radiotherapy at the National Institute of Cancer Research & Hospital (NICRH). Her involvement with the national institute keeps her at the forefront of cancer research and treatment protocols in Bangladesh.
Areas of Clinical Expertise
Dr. Shahida Alam Lima specializes in the non-surgical treatment of cancer, focusing on:
- Radiation Therapy: Precision application of high-energy beams to target and shrink tumors.
- Chemotherapy & Systemic Therapy: Coordinating drug treatments to manage cancer cell growth.
- Gynecological & Breast Cancer: Specialized focus on cancers affecting women.
- Early Detection & Screening: Providing vital diagnostic guidance for early-stage malignancies.
